Tyra Biosciences
TYRA
170 hedge funds and large institutions have $2.22B invested in Tyra Biosciences in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 44 reducing their positions, and 25 closing their positions.
605% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $1.92M
66% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 44
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
4% more funds holding
Funds holding: 164 → 170 (+6)
5.8% less ownership
Funds ownership: 122.41% → 116.61% (-5.8%)
12% less capital invested
Capital invested by funds: $2.52B → $2.22B (-$309M)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$59.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.8M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$33.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$30.6M |
| 5 |
BlackRock
New York
|
+$26.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$137M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$32.6M |
| 3 |
Barclays
London,
United Kingdom
|
-$26.9M |
| 4 |
CC
Commodore Capital
New York
|
-$19.8M |
| 5 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$16.6M |
TYRA Hedge Fund Activity: Q2 2026 in Review
170 institutional investors reported a position in Tyra Biosciences (TYRA) for Q2 2026, worth a combined $2.22B — down 12% from $2.52B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TYRA positions and 25 closed out — a net gain of 8 holders — while 73 added to existing stakes and 44 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $59.4M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $137M sold.
- 170 institutional investors held Tyra Biosciences (TYRA) as of Q2 2026, up from 164 in Q1 2026.
- Funds reported $2.22B of Tyra Biosciences stock for Q2 2026, down 12% quarter-over-quarter.
- 33 funds opened new Tyra Biosciences positions in Q2 2026 and 25 closed out, a net change of +8 holders.
- The largest Tyra Biosciences buyer in Q2 2026 was T. Rowe Price Associates, an estimated $59.4M added.
- The largest Tyra Biosciences seller in Q2 2026 was Farallon Capital Management, an estimated $137M sold.
Based on aggregated 13F filings for Q2 2026.